In parallel, it has been demonstrated that the addition of an anti-TGF-β agent increases the efficacy of ICI treatments in animal models of lung and breast cancer [29,30], although they did not assess the specific changes in neutrophils following this treatment. Here, TGFB1 is linked to breast carcinoma.